The global market for artificial intelligence in omics studies is growing at a breakneck pace, expanding from $1.25 billion in 2025 to an expected $6.11 billion by 2035, according to new market analysis. This 17.2% annual growth rate reflects a fundamental shift in how hospitals, pharmaceutical companies, and research institutions are approaching disease treatment and drug development. Rather than relying on traditional analytical methods that struggle with massive datasets, organizations are increasingly turning to AI to unlock insights hidden within genomic, proteomic, and metabolomic data .

Why Is AI Suddenly Essential for Understanding Your Genes?

The explosion in biological data has outpaced human ability to analyze it. Modern sequencing technologies generate staggering volumes of genetic information, but traditional methods cannot process this complexity at scale. AI algorithms, particularly machine learning and deep learning systems, can identify patterns in this data that would be impossible for researchers to spot manually. This capability is transforming how scientists approach everything from identifying disease biomarkers to predicting which drug compounds will actually work in patients .

The shift toward precision medicine is a major driver of this market expansion. Instead of prescribing the same treatment to all patients with a condition, AI enables doctors to tailor therapies based on an individual's unique genetic and molecular profile. This approach is already reshaping oncology, where cancer treatments are increasingly customized to match specific tumor characteristics. As healthcare systems adopt multi-omics strategies, AI is moving from the research lab into hospitals and clinics, making personalized treatment more accessible and effective .

How Are Companies Actually Using AI in Omics Research?

• Drug Discovery: AI accounts for 35% of the omics market's applications, helping pharmaceutical companies identify drug targets faster and reduce development timelines. By analyzing vast datasets of molecular interactions, AI can predict which compounds are most likely to succeed, reducing the expensive trial-and-error phase of drug development.
• Genomic Analysis: Genomics holds the largest market share at 40%, driven by large-scale DNA sequencing data and AI's ability to detect genetic variants and support personalized medicine decisions. This segment is clinically relevant because it directly informs treatment choices.
• Protein Structure Prediction: Proteomics, the study of proteins, represents 20% of the market and is growing rapidly. AI's ability to predict protein structures and map molecular interactions helps researchers identify new drug targets and understand disease mechanisms beyond what genetics alone can reveal.

Software solutions dominate the market, accounting for 55% of revenue in 2025. These tools are critical because they transform raw, unstructured omics data into actionable insights that clinicians and researchers can actually use. Services, which include AI model building, data analytics consulting, and infrastructure support, represent the second-largest segment. Many smaller research institutions lack the computational expertise and infrastructure to build these systems themselves, so they outsource to specialized firms .

Recent industry moves underscore the momentum. In October 2025, Illumina, a major DNA sequencing company, launched a new business focused on informatics and AI software specifically designed for drug developers analyzing large amounts of DNA sequencing and multi-omics data. The company also acquired SomaLogic, a proteomics firm, for $425 million, signaling confidence in the market's future. Meanwhile, BioAro launched PanOmiQ Research in June 2025, positioning it as the first comprehensive, scalable platform that connects omics analysis directly to drug development .

Who Is Investing in This Technology, and Where?

Pharmaceutical and biotechnology companies account for 50% of the market, driven by their massive investments in AI-enhanced drug discovery and their need to improve drug pipelines and reduce attrition rates. Research institutes hold the second-largest share and are expected to grow significantly, as they remain key innovators in genomics and multi-omics research .

Geographically, North America dominates with 42% of the global market, powered by strong capital investment, advanced computational infrastructure, and robust research ecosystems. The United States leads with large-scale sequencing initiatives and significant private funding, while Canada contributes through strong academic-industry partnerships. This has transformed omics from an experimental field into an operational one, where AI is now central to analysis rather than an optional add-on .

Asia Pacific is expected to grow fastest during the forecast period. China is positioned to lead this region with government-backed genomics programs and widespread AI integration, while India is contributing through growing research and development funding. Japan and South Korea are supporting market growth with their emphasis on precision medicine applications .

What Does This Mean for Patients and Researchers?

The expansion of AI in omics research has practical implications across multiple domains. For patients, it means faster diagnosis, more targeted treatments, and better outcomes as precision medicine becomes routine rather than experimental. For researchers, it means they can tackle biological questions that were previously intractable due to data complexity. For pharmaceutical companies, it means shorter drug development timelines and higher success rates, potentially bringing life-saving treatments to market years faster than traditional approaches .

The market's rapid growth reflects confidence that AI will continue to unlock biological insights at an accelerating pace. As computational costs decline and AI technologies mature, adoption is spreading beyond elite research institutions to smaller organizations and healthcare providers. This democratization of AI-powered omics analysis could fundamentally reshape how medicine is practiced globally, making personalized, data-driven treatment accessible to far more patients than ever before.